Home

About Us

Capabilities

GLP accreditation

How To Find Us

In Vitro Absorption

Additional Services

Advisory Board

Guidelines

Job Vacancies

Sponsors / Charity

Awards & Publicity

DTL’s Managing Director, Dave Fox, was the Head of the in vitro percutaneous absorption group at Syngenta CTL. Dave has over 20 years experience in toxicology and management at CTL’s laboratories at Alderley Park. In 2003, Dave obtained a MBA from Manchester Business School.

Professor Jon Heylings, Chairman of DTL, has more than 30 years experience as a Senior Toxicologist and Section Head at Syngenta CTL and holds the honorary position of Professor of Toxicology in the School of Pharmacy at Keele University.  Jon has worked with OECD, WHO and several UK and European Industry and Government bodies to develop and advocate alternative (non-animal) methods to evaluate the dermal absorption of chemicals.

Dermal Technology Laboratory (DTL Ltd) was founded in February 2007, by David Fox and Jon Heylings, following the closure of Syngenta’s Central Toxicology Laboratory (CTL) at Alderley Park, Cheshire, UK. DTL is based at the Medical Innovation Centre 4 facility at Keele University Science and Business Park in a modern and adaptable facility in a developing prestigious biomedical environment.

The brand new facilities at Keele and the image they portray fits well with the Company’s goal to be state-of-the-art in its technical field. DTL moved into the Science and Business Park on the Keele campus in April 2007 and gained full membership of the UK GLP Monitoring Authority Programme in July 2007.